Surgical Management of Ménière's Disease

(50-Mark Answer — RGUHS Standard)

INTRODUCTION

• Episodic vertigo (30 min – several hours)
• Fluctuating sensorineural hearing loss (low-frequency, initially)
• Tinnitus
• Aural fullness

INDICATIONS FOR SURGERY

1. Medical management has failed after 6–12 months
2. Patient has disabling vertigo affecting quality of life
3. Attacks are frequent and severe (≥3 definitive attacks/6 months despite treatment)
4. Medical: low-salt diet, diuretics, vestibular suppressants, betahistine have failed
5. Before ablative surgery — intratympanic gentamicin (chemical ablation) is usually tried

CLASSIFICATION OF SURGICAL PROCEDURES

╔══════════════════════════════════════════════════════════════╗
║           SURGERIES FOR MÉNIÈRE'S DISEASE                  ║
╠══════════════════════╦═══════════════════════════════════════╣
║  CONSERVATIVE        ║       ABLATIVE / DESTRUCTIVE         ║
║  (Hearing Preserving)║                                       ║
╠══════════════════════╬═══════════════════════════════════════╣
║  1. Endolymphatic    ║  A. CHEMICAL ABLATION                ║
║     Sac Surgery:     ║     • Intratympanic Gentamicin       ║
║     a) Decompression ║       (IT Aminoglycoside)            ║
║     b) Shunts        ║  B. SURGICAL ABLATION               ║
║        (mastoid,     ║     • Cochleosacculotomy             ║
║         subarachnoid)║     • Labyrinthectomy:               ║
║  2. Cochleosacculotomy║       – Transcanal (Cody tack)      ║
║     (elderly/poor    ║       – Transmastoid                 ║
║      hearing)        ║       – Translabyrinthine           ║
║  3. Vestibular       ║  C. NEURECTOMY                      ║
║     Neurectomy       ║     • Vestibular Nerve Section:      ║
║     (hearing present)║       – Middle fossa approach        ║
║                      ║       – Retrolabyrinthine            ║
║                      ║       – Retrosigmoid/posterior fossa ║
╚══════════════════════╩═══════════════════════════════════════╝

PREOPERATIVE EVALUATION

1. Audiometry — establishes hearing level, identifies pathologic ear
2. Electronystagmography (ENG)/Videonystagmography (VNG) — caloric testing, identifies side
3. Electrocochleography (ECochG) — elevated summating potential/action potential ratio (>0.35) supports hydrops
4. MRI of posterior fossa with gadolinium — mandatory to exclude acoustic neuroma, demyelinating disease, brainstem ischemia
5. Glycerol dehydration test — improvement in PTA >10 dB or speech discrimination >12% confirms hydrops
6. Identification of the offending labyrinth:
   • Most reliable: fluctuating/progressive unilateral SNHL
   • Reproducible unilateral caloric reduction
   • Asymmetric hearing loss = best indicator

"If uncertainty arises regarding the ear causing vertigo, ablative surgery should not be considered." — Cummings Otolaryngology

FLOWCHART: MANAGEMENT ALGORITHM FOR MÉNIÈRE'S DISEASE

                    MÉNIÈRE'S DISEASE
                          │
                ┌─────────▼──────────┐
                │  MEDICAL MANAGEMENT│
                │ • Low-salt diet    │
                │ • Diuretics        │
                │ • Betahistine      │
                │ • Vestibular       │
                │   suppressants     │
                └─────────┬──────────┘
                          │
              ┌───────────▼────────────────────┐
              │ Controlled? YES → Continue Rx   │
              └───────────┬────────────────────┘
                          │ NO (>6–12 months failure)
                          ▼
              ┌───────────────────────────────┐
              │ INTRATYMPANIC GENTAMICIN       │
              │ (Chemical Labyrinthectomy)     │
              └───────────┬───────────────────┘
                          │
              ┌───────────▼──────────────────┐
              │  ASSESS RESIDUAL HEARING      │
              └──────┬────────────────────┬──┘
                     │                    │
              ┌──────▼──────┐      ┌──────▼──────┐
              │ USEFUL      │      │  NO USEFUL  │
              │ HEARING     │      │  HEARING    │
              │ PRESENT     │      │  (PTA>60dB) │
              └──────┬──────┘      └──────┬──────┘
                     │                    │
       ┌─────────────┼──────────┐   ┌─────▼──────────────┐
       ▼             ▼          ▼   │  LABYRINTHECTOMY    │
Endolymphatic  Vestibular  IT Steroids  │  (Transmastoid or  │
Sac Surgery    Neurectomy  (adjunct)    │  Translabyrinthine)│
               (MFC/retro  Cochleosac- └────────────────────┘
               labyrinthine) culotomy
               Retrosigmoid  (elderly)

A. CONSERVATIVE (HEARING-PRESERVING) PROCEDURES

1. ENDOLYMPHATIC SAC SURGERY

Anatomy of the Endolymphatic Sac

• The endolymphatic sac (ES) is a blind-ending epithelial sac located in the posterior cranial fossa, between layers of the dura mater near the sigmoid sinus
• It lies in the Trautmann's triangle (bounded by sigmoid sinus posteriorly, posterior semicircular canal anteriorly, superior petrosal sinus superiorly)
• The endolymphatic duct connects the saccule and utricle to the sac via the vestibular aqueduct

Rationale

• Decompress the sac (reduce pressure)
• Create a drainage pathway (shunt)

Types of Endolymphatic Sac Procedures

1. Mastoidectomy — complete simple mastoidectomy performed
2. The sigmoid sinus and posterior semicircular canal are skeletonized
3. Bone over the posterior fossa dura is removed in Trautmann's triangle
4. The endolymphatic sac is identified as a thickened white structure in the posterior fossa dura
5. The sac is exposed but the lumen is not opened
6. Removal of the bone overlying the sac reduces pressure

• Bill's island: a knob of bone between the posterior semicircular canal and the sigmoid sinus
• Donaldson's line: a line drawn through the horizontal semicircular canal, parallel to the lateral semicircular canal — the ES lies below this line

• Endolymphatic-mastoid shunt: Sac is opened and a T-tube/silastic tube placed from the sac lumen into the mastoid cavity
• Endolymphatic-subarachnoid shunt: Tube drains into the posterior cranial fossa CSF — higher rates of CSF leak, meningitis; largely abandoned
• Summerskill's procedure (endolymphatic sac incision): Simple incision of the sac

• Vertigo control in 60–80% at 2 years
• Hearing preservation in most
• Controversy: The classic Thomsen et al. double-blind placebo-controlled study (Denmark) showed endolymphatic sac shunt surgery was no better than mastoidectomy alone (placebo effect of surgery), calling the procedure's specific efficacy into question
• Despite controversy, ESD remains widely practiced as it is the least invasive surgical option and has a low complication rate

2. COCHLEOSACCULOTOMY (FICK OPERATION)

1. A pick (Fick's pick) is introduced through the round window membrane into the scala tympani
2. The instrument is advanced to perforate the basilar membrane and then the saccular wall (Reissner's membrane area), creating a communication between endolymph and perilymph
3. This allows decompression of the endolymphatic space

• Vertigo control: ~70%
• Risk: further deterioration of already poor hearing
• Crude but effective under local anesthesia in elderly patients

B. ABLATIVE PROCEDURES — LABYRINTHECTOMY

• Non-serviceable hearing (PTA >60–70 dB or speech discrimination <50%)
• Unilateral MD with intractable vertigo
• Older patients with poor hearing

TYPES OF LABYRINTHECTOMY

a) Transcanal (Oval Window) Labyrinthectomy

• Performed through the external auditory canal
• Stapes removed, perilymph aspirated
• Neuroepithelium of the semicircular canals and saccule curetted out
• Simpler but limited access

b) Transmastoid Labyrinthectomy

1. Complete mastoidectomy performed
2. Incus removed for improved access
3. All three semicircular canals are opened and the membranous labyrinth drilled out
4. Utricle and saccule are removed
5. Vestibular end organs are completely ablated
6. Cochlea may be preserved (cochlea is not drilled)
7. Fat obliteration of the cavity optional

• Better access than transcanal
• Can be combined with cochlear implantation (simultaneous labyrinthectomy + CI)
• Lower morbidity than translabyrinthine approach

c) Translabyrinthine Labyrinthectomy

• Used primarily when an acoustic neuroma co-exists
• Provides wide posterior fossa access
• Complete labyrinth sacrificed including cochlea and vestibule
• Used rarely for MD alone; more for vestibular schwannoma

• Vertigo control: 95–98% (best control of all surgical options)
• Hearing: sacrificed completely
• Facial nerve: at risk if anatomy is distorted (must be identified)
• Requires central vestibular compensation postoperatively — rehabilitation needed

C. VESTIBULAR NEURECTOMY (VESTIBULAR NERVE SECTION)

• Intractable MD with serviceable hearing (PTA <50 dB, speech discrimination >50%)
• Failed endolymphatic sac surgery
• Failed intratympanic gentamicin
• Bilateral vestibular dysfunction excluded

Surgical Approaches to Vestibular Neurectomy

a) Retrolabyrinthine Vestibular Neurectomy

• Developed by Silverstein and Norrell
• Mastoidectomy → bone posterior to posterior semicircular canal removed → posterior fossa dura opened posterior to the labyrinth
• Vestibular nerve section performed in the posterior cranial fossa just medial to the internal auditory canal (IAC)
• Cochlear and facial nerves identified and preserved
• Advantage: Less cerebellar retraction, lower CSF leak risk
• Disadvantage: Restricted access, challenging visualization of nerve branches

b) Middle Cranial Fossa (Middle Fossa) Vestibular Neurectomy

• Developed by House; indicated especially for selective superior vestibular neurectomy
• Temporal craniotomy above the zygomatic arch → extradural elevation of temporal lobe
• IAC identified from above
• Superior vestibular nerve selectively sectioned (posterior ampullary nerve and main superior division)
• Advantage: Excellent exposure of superior vestibular nerve; cochlear nerve easily identified and preserved
• Disadvantage: Risk of temporal lobe retraction injury, epidural hematoma; technically demanding; not suitable for elderly/poor surgical candidates

c) Retrosigmoid (Posterior Fossa) Vestibular Neurectomy

• Retrosigmoid/suboccipital craniectomy → posterior cranial fossa
• Internal auditory canal drilled open from posterior
• Vestibular nerve branches sectioned under direct vision
• Advantage: Wide exposure, good visualization of all nerve divisions, suitable for all age groups
• Disadvantage: Higher rate of postoperative headache; cerebellar retraction needed; CSF leak risk

Nerve Identification During Neurectomy

In the IAC (from superior to inferior):
┌─────────────────────────────────┐
│  Superior Vestibular Nerve       │ ← SECTION
│  (Facial nerve anterior to it)   │
├─────────────────────────────────┤
│  Inferior Vestibular Nerve       │ ← SECTION
├─────────────────────────────────┤
│  Cochlear Nerve                  │ ← PRESERVE
├─────────────────────────────────┤
│  Facial Nerve (anterior-superior)│ ← PRESERVE
└─────────────────────────────────┘
Bill's bar separates facial nerve
from superior vestibular nerve

• Vertigo control: 90–95%
• Hearing preservation: 60–85% depending on approach
• Facial nerve injury: <1–2% in experienced hands
• CSF leak: 2–5%

D. INTRATYMPANIC AMINOGLYCOSIDE ABLATION (CHEMICAL LABYRINTHECTOMY)

• Intratympanic gentamicin (IT Gentamicin):
  • Gentamicin is specifically vestibulotoxic at low doses (spares cochlear hair cells at lower concentrations vs. streptomycin which is more cochleotoxic)
  • Administered via myringotomy and injection into the middle ear, diffuses through the round window
  • Multiple dosing protocols: weekly injections (titration protocol) vs. fixed-dose
  • Vertigo control: 80–90%; risk of additional SNHL: 10–30% (dose-dependent)
  • Currently considered first-line ablative therapy before open surgical ablation (Cummings)
• Intratympanic streptomycin: More cochleotoxic; used historically for bilateral MD

E. INTRATYMPANIC STEROIDS (NON-ABLATIVE)

• Dexamethasone or methylprednisolone injected intratympanically
• Mechanism: anti-inflammatory, mineralocorticoid effects on Na⁺-K⁺ channels in endolymph homeostasis
• Itoh & Sakata (1987): first IT steroid protocol — 4–5 weekly 2 mg dexamethasone injections → vertigo relief in 80%, tinnitus reduction in 74%
• Advantage: No ablative risk, reversible
• Limitation: No effect on hearing; efficacy uncertain in RCTs

COMPARATIVE SUMMARY TABLE

DECISION-MAKING FLOWCHART (HEARING-BASED)

INTRACTABLE MÉNIÈRE'S DISEASE
(Failed Medical + IT Gentamicin)
              │
    ┌─────────▼──────────┐
    │   ASSESS HEARING   │
    └─────┬──────────┬───┘
          │          │
    ┌─────▼────┐  ┌──▼──────────────┐
    │SERVICEABLE│  │NON-SERVICEABLE  │
    │ HEARING  │  │ HEARING         │
    │PTA <50 dB│  │PTA >60 dB or   │
    │SD >50%   │  │SD <50%          │
    └─────┬────┘  └──┬──────────────┘
          │          │
    ┌─────▼────┐  ┌──▼──────────────┐
    │Endolymph-│  │ LABYRINTHECTOMY │
    │atic Sac  │  │ (Transmastoid)  │
    │Surgery   │  │ Vertigo control │
    │(1st line)│  │ 95–98%          │
    └─────┬────┘  └─────────────────┘
          │
    ┌─────▼────────────────┐
    │ Failed ELS surgery?  │
    └─────┬────────────────┘
          │ YES
    ┌─────▼────────────────────────────┐
    │ VESTIBULAR NEURECTOMY            │
    │ Choose approach:                 │
    │ • Young/fit → Middle fossa       │
    │ • General → Retrosigmoid         │
    │ • Less invasive → Retrolabyrinth │
    └──────────────────────────────────┘

ENDOLYMPHATIC SAC — SURGICAL ANATOMY DIAGRAM

         TEMPORAL BONE (POSTERIOR VIEW)
         
  Superior Petrosal Sinus ────────────────┐
                                          │
  Posterior Semicircular Canal ─┐         │
                                │         │
  TRAUTMANN'S TRIANGLE          │         │
  (Site of Endolymphatic Sac)   │         │
         ┌──────────────────────┐         │
         │   ENDOLYMPHATIC SAC  │         │
         │   (in dura mater)    │         │
         └──────────────────────┘         │
                                │         │
  Sigmoid Sinus ────────────────┘─────────┘
  
  Jugular Bulb ────── inferior boundary
  
  DONALDSON'S LINE: parallel to lateral SCC
  → ES lies BELOW this line
  
  BILL'S ISLAND: bony knob between
  posterior SCC and sigmoid sinus
  → ES lies MEDIAL to this landmark

MRI IMAGE: Endolymphatic Hydrops — Pre and Post Surgery

RECENT ADVANCES (2018–2024)

1. MRI Endolymphatic Hydrops Grading (Intravenous Gadolinium MRI)
   • 3D real inversion recovery (3D-real IR) sequences after delayed IV or IT gadolinium
   • Allows non-invasive visualization and grading of hydrops (cochlear and vestibular compartments)
   • Guides surgical decision-making and monitors post-surgical outcomes
   • Vestibular Hydrops Ratio (VHR) measured quantitatively
2. Minimally Invasive Endolymphatic Sac Surgery
   • Endoscope-assisted ESD — reduced retraction, better visualization without full mastoidectomy
   • Transmastoid approaches refined with image-guided navigation
3. Cochlear Implantation + Simultaneous Labyrinthectomy
   • For patients with end-stage bilateral MD or unilateral MD with profound SNHL
   • Labyrinthectomy performed simultaneously with CI insertion
   • Provides both vestibular control AND auditory rehabilitation in a single procedure (Alarcon et al., 2017)
4. IT Gentamicin — Low-Dose Titration Protocols
   • "On-demand" or symptom-triggered protocols
   • Single low-dose injections with re-treatment only if vertigo recurs
   • Reduces risk of hearing loss (Kaylie et al., 2020)
5. Endolymphatic Sac Electrocautery
   • Electrosurgical enhancement of ES decompression using bipolar cautery to create fibrous adhesions
   • Preliminary results show improved vertigo control vs. decompression alone
6. Pressure Therapy: Meniett Device
   • Non-surgical: applies micropressure pulses via tympanostomy tube
   • Thought to facilitate endolymph resorption via pressure transmission
   • FDA-approved; used as bridge between medical and surgical therapy
7. Gene Therapy (Experimental)
   • Aquaporin-2 and Aquaporin-4 channels regulate endolymph homeostasis
   • Gene modulation to normalize fluid transport — animal models promising
   • Human trials pending
8. Vestibular Implants (Research Stage)
   • Analog of cochlear implant for vestibular system
   • Stimulates vestibular nerve electrically after labyrinthectomy
   • Potential future application in bilateral MD

COMPLICATIONS OF SURGERY

IMPORTANT HISTORICAL CONTRIBUTIONS

SUMMARY MNEMONICS

• C — Cochleosacculotomy (elderly, local anesthesia)
• L — Labyrinthectomy (no useful hearing)
• E — Endolymphatic sac surgery (first line, hearing present)
• V — Vestibular neurectomy (hearing present, failed ELS)
• E — Electrolytic/chemical ablation (IT gentamicin)
• R — Retrolabyrinthine/Retrosigmoid/middle fossa (approaches for neurectomy)

REFERENCES (Textbook Sources)

• Cummings Otolaryngology — Head and Neck Surgery (7th ed., Flint et al.) — Chapters 158 (Intratympanic Drug Therapy) and 165 (Surgical Management of Vestibular Disorders), pp. 3034–3260
• KJ Lee's Essential Otolaryngology (11th ed.) — Ménière Disease, pp. 76–77
• Scott-Brown's Otolaryngology, Head and Neck Surgery — Ménière disease management (standard reference per RGUHS syllabus)
• Dhingra's Diseases of Ear, Nose and Throat — Meniere's disease and surgical management
• Hazarika's Textbook of ENT and Head Neck Surgery — Meniere's disease surgery
• Harrison's Principles of Internal Medicine (22nd ed.) — Sensorineural Hearing Loss and Vertigo chapter: "Surgical therapy of vertigo is reserved for unresponsive cases and includes endolymphatic sac decompression, labyrinthectomy, and vestibular nerve section. Both labyrinthectomy and vestibular nerve section abolish rotary vertigo in >90% of cases."

Note on generate_image: The image generation feature is currently unavailable on your plan (monthly limit reached). The flowcharts and anatomical diagrams above are rendered as detailed ASCII/text diagrams. To upgrade for image generation, please contact support or upgrade your subscription plan.